Investigating SOcial Competence and Isolation in children with Autism taking part in LEGO-based therapy clubs In School Environments (I-SOCIALISE): study protocol.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
01 06 2019
Historique:
entrez: 3 6 2019
pubmed: 4 6 2019
medline: 19 5 2020
Statut: epublish

Résumé

Social skills training interventions for children with autism spectrum disorder (ASD) typically focus on a skills deficit model rather than building on existing skills or encouraging the child to seek their own solutions. LEGO-based therapy is a child-oriented intervention to help improve social interactional skills and reduce isolation. The therapy is designed for school-age children with ASD and uses group-based play in a school setting to encourage peer relationships and social learning. Despite the reported potential benefits of LEGO-based therapy in a prior randomised controlled trial (RCT) and its adoption by many schools, the evidence to support its effectiveness on the social and emotional well-being of children with ASD is limited and includes no assessment of cost-effectiveness. This multicentre, pragmatic, cluster RCT will randomise 240 participants (aged 7-15 years) with a clinical diagnosis of ASD to receive usual care or LEGO-based therapy with usual care. Cluster randomisation will be conducted on a school level, randomising each school as opposed to each individual child within a school. All prospective participants will be screened for eligibility before assenting to the study (with parents giving informed consent on behalf of their child). All participants will be followed up at 20 and 52 weeks after randomisation to assess for social, emotional and behavioural changes. The primary outcome measure is the social skills subscale of the Social Skills Improvement System completed by a teacher or teaching assistant associated with participating children at the 20-week follow-up time point. Ethics approval has been obtained via the University of York Research Ethics Committee. The results of the trial will be submitted for publication in a peer-reviewed journal and will be disseminated to participating families, education practitioners and the third sector including voluntary and community organisations. ISRCTN64852382; Pre-results.

Identifiants

pubmed: 31154316
pii: bmjopen-2019-030471
doi: 10.1136/bmjopen-2019-030471
pmc: PMC6549632
doi:

Banques de données

ISRCTN
['ISRCTN64852382']

Types de publication

Clinical Trial Protocol Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e030471

Subventions

Organisme : Department of Health
ID : PHR/15/49/32
Pays : United Kingdom

Informations de copyright

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: The research team are aware that the LEGO name is a registered trademark and will follow their fair use policy in regard to the LEGO brand throughout the duration of the trial. Co-applicant Gina Gomez de la Cuesta coauthored the LEGO-based therapy manual 17 which will form the basis of the LEGO-based therapy delivered in the trial. The coauthors of the manual have given us full permission to use the manual without licence and to develop an abridged version. They have also stated their support for us in writing our own version, and will become coauthors on any future publications. Co-applicant Gomez has also agreed for the team to adapt the fidelity checklist used in her previous study. We have provisional agreement with Jessica Kingsley Publishers who have expressed interest in publishing the abridged manual. However, we are not tied to them as a publisher. There are no other financial and/or competing interests to declare.

Références

J Child Psychol Psychiatry. 2004 Feb;45(2):212-29
pubmed: 14982237
Appl Health Econ Health Policy. 2011 May 1;9(3):157-69
pubmed: 21506622
J Autism Dev Disord. 2007 Feb;37(2):230-42
pubmed: 16855874
J Autism Dev Disord. 2008 Apr;38(4):739-47
pubmed: 17764027
J Autism Dev Disord. 2001 Jun;31(3):315-25
pubmed: 11518484
J Child Psychol Psychiatry. 1997 Jul;38(5):581-6
pubmed: 9255702
J Consult Clin Psychol. 2005 Oct;73(5):852-60
pubmed: 16287385
J Autism Dev Disord. 2008 Nov;38(10):1944-57
pubmed: 18566882
BMC Health Serv Res. 2007 Sep 19;7:148
pubmed: 17880693
Int J Lang Commun Disord. 2009 Jul-Aug;44(4):511-28
pubmed: 19340628
J Autism Dev Disord. 2001 Apr;31(2):119-30
pubmed: 11450811
BMJ. 1999 Sep 11;319(7211):703-4
pubmed: 10480833
Health Technol Assess. 2016 Jan;20(6):1-258
pubmed: 26792796
Clin Child Psychol Psychiatry. 2011 Jan;16(1):5-20
pubmed: 20223793
Br J Psychiatry. 2009 Jun;194(6):500-9
pubmed: 19478287
Autism. 2003 Mar;7(1):81-97
pubmed: 12638766
BMC Health Serv Res. 2017 Jan 26;17(1):88
pubmed: 28126032
Child Dev. 1998 Feb;69(1):140-53
pubmed: 9499563
Cochrane Database Syst Rev. 2012 Jul 11;(7):CD008511
pubmed: 22786515
Health Policy. 1990 Dec;16(3):199-208
pubmed: 10109801
Can J Psychiatry. 2012 May;57(5):275-83
pubmed: 22546059

Auteurs

Danielle Varley (D)

COMIC, Leeds and York Partnership NHS Foundation Trust, York, UK.

Barry Wright (B)

Department of Health Sciences, University of York, York, UK.
Hull York Medical School, University of York, York, England.

Cindy Cooper (C)

ScHARR, University of Sheffield, Sheffield, UK.

David Marshall (D)

Department of Health Sciences, University of York, York, UK.

Katie Biggs (K)

Clinical Trials Research Unit, University of Sheffield, Sheffield, UK.

Shehzad Ali (S)

Department of Health Sciences, University of York, York, UK.
Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.

Tim Chater (T)

School of Health and Related Research, University of Sheffield, Sheffield, UK.

Elizabeth Coates (E)

School of Health and Related Research, University of Sheffield, Sheffield, UK.

Simon Gilbody (S)

Department of Health Sciences, University of York, York, UK.

Gina Gomez de la Cuesta (G)

Cambridgeshire Community Services NHS Trust, Cambridge, UK.

Ellen Kingsley (E)

Leeds and York Partnership NHS Foundation Trust, York, UK.

Ann Le Couteur (A)

Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK.

Anne McKelvey (A)

City of York Council, York, UK.

Neil Shephard (N)

Clinical Trials Research Unit, University of Sheffield, Sheffield, UK.

Dawn Teare (D)

School of Health and Related Research, University of Sheffield, Sheffield, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH